Showing 4461-4470 of 7542 results for "".
- Study: Severe Psoriasis More Common in Menhttps://practicaldermatology.com/news/severe-psoriasis-more-common-in-men/2458235/Severe psoriasis predominantly affects men, according to a new study in the American Journal of Clinical Dermatology. In the study of 5,438 Swedish psoriasis patients, women had significantly (p<0.
- FDA Approves First Treatment for Rare Form of Skin Cancerhttps://practicaldermatology.com/news/fda-approves-first-treatment-for-rare-form-of-skin-cancer/2458236/The FDA granted accelerated approval to Bavencio (avelumab) for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC), including those who have not received prior chemotherapy. This is the first FDA-approved treatment for metastatic MCC, a r
- FDA Approved Juvéderm Vollure XC for Correction of Facial Wrinkles and Foldshttps://practicaldermatology.com/news/fda-approved-juvderm-vollure-xc-for-correction-of-facial-wrinkles-and-folds/2458241/The FDA has approved Allergan plc's Juvéderm Vollure XC for correction of moderate to severe facial wrinkles and folds, such as nasolabial folds, in adults over the age of 21. In the US pivotal clinical trial, a majority (59 percent) of subjects saw improvement in moderate to severe na
- Education Credits Available: ABCs of Nitric Oxide in the Skinhttps://practicaldermatology.com/news/education-credits-available-abcs-of-nitric-oxide-in-the-skin/2458239/A free, online educational program intended to provide participants increased knowledge regarding the role of NO in maintaining a variety of physiologic processes has been launched. The program is directed by James Q. Del Rosso, DO. The program is also intended to address the correlation of
- RepliCel's Baldness Cure Performs Well In First In-Human Trialhttps://practicaldermatology.com/news/replicels-baldness-cure-performs-well-in-first-in-human-trial/2458246/The first in-human study of RepliCel Life Sciences Inc’s investigational baldness cure, RCH-01, confirms the therapy’s safety and demonstrates strong efficacy signals, the company reports. The autologous cell therapy involves culturing a person’s own dermal sheath cup ce
- Pershing Square Capital Management, L.P. Announces Sale of Its Investment In Valeant Pharmaceuticals International, Inc.https://practicaldermatology.com/news/pershing-square-capital-management-lp-announces-sale-of-its-investment-in-valeant-pharmaceuticals-international-inc/2458249/Pershing Square Capital Management, L.P. (“Pershing Square”) announced today that it has sold its investment in Valeant Pharmaceuticals International, Inc. (“Valeant”) (ticker: NYSE: VRX). Pershing Square CEO Bill Ackman and Vice Chairman Steve Fraidin will remain on the V
- New Research Closes In On Personalized AD Therapyhttps://practicaldermatology.com/news/new-research-closes-in-on-personalized-therapy-for-ad/2458254/New research on skin lipids may pave the way toward personalized therapies for atopic dermatitis. Researchers can now identify the precise lipids found in the skin of people who have atopic dermatitis, and compare them to people with healthy skin. Here’s how: A type of tape can pull
- Pierre Fabre and Hill Dermaceuticals Partner in Commercial Partnership for TOLAK for AKshttps://practicaldermatology.com/news/pierre-fabre-and-hill-dermaceuticals-partner-in-commercial-partnership-for-tolak-for-aks/2458258/Pierre Fabre Dermo-Cosmetique and Hill Dermaceuticals, Inc. have entered into a strategic commercial partnership for TOLAK, a patented prescription dermatologic drug, indicated for the topical treatment of actinic keratosis lesions of the face, ears, and/or scalp. Under the terms of the a
- Zeltiq Shines Spotlight on CoolAdvantage Petite Applicator at AAD Annual Meetinghttps://practicaldermatology.com/news/zeltiq-shines-spotlight-on-coolmini-applicator-at-aad-annual-meeting/2458259/ZELTIQ® Aesthetics is showcasing the CoolAdvantage Petite™ applicator at the American Academy of Dermatology Annual Meeting (AAD) in Orlando. The CoolAdvantage technology is the only non-invasive fat removal technology cleared by the Food and Drug Administration (F
- Cutanea Unveils Aktipak Gel, 3%/5%, Convenient Acne Treatment for "On-the-Go" Patientshttps://practicaldermatology.com/news/cutanea-unveils-aktipak-gel-35-convenient-acne-treatment-for-on-the-go-patients/2458260/Cutanea Life Sciences, Inc. (CLS) introduced Aktipak (erythromycin and benzoyl peroxide) Gel, 3%/5%, a combination therapy indicated for the topical treatment of acne vulgaris. The product is available through dermatologists' offices. Aktipak is a portable, freshly mixed, p